{"prompt": "['Protocol RS-001', 'Confidential', '3.3', 'Exploratory Objectives', 'For children enrolled in the study who underwent epilepsy surgery at our institution, informed', 'consent will be sought for us to use their previously acquired/banked surgical tissue (including', 'fibroblast cultures) for the following exploratory aims:', 'To explore associations between histopathologic diagnosis and seizure outcomes', 'To explore associations between pS6 positivity and seizure outcomes', 'To analyze key molecular features including activation of the PI3K, mTOR and MAPK', 'pathways as they relate to seizure outcomes', 'To possibly perform additional genomic studies or obtain previously performed genomic', 'analyses including genomic profiling from peripheral samples and correlate to seizure', 'outcomes', 'Explore any relationships between safety, efficacy and whole blood rapamycin trough', 'levels', 'Explore any relationships between AED levels (acquired outside the study through', 'clinical standard of care) and rapamycin levels during the study', 'None of the exploratory aims would require additional experimental procedures to the', 'participants throughout the study beyond those explicitly discussed in the protocol. Tissue', 'would only be tested on participants who have already consented to and have banked tissue', 'within our institution from prior epilepsy-related procedures.', '4', 'STUDY DESIGN', '4.1', 'Study Overview', 'This is a prospective, single-center, non-randomized open-label phase 1 study to investigate', 'multiple dose levels of ABI-009 for surgically-refractory epilepsy. Up to 18 participants are', 'planned to be enrolled into the study.', 'The duration of participation for each participant is up to 18 weeks, including a 4-week baseline', 'period to obtain baseline outcome rates, a 3-week active study period and a 12-week follow-up', 'period (see Figure 1). After the baseline period, participants will be started on the assigned dose', 'of ABI-009, given once weekly for a total of 3 weeks. Dose levels to be tested are below:', 'For dose finding, ABI-009 will be tested in cohorts of 3 participants each using the standard 3+3', 'dose-finding design. Initial starting dose will be at 5 mg/m2/week.', 'Table 3: ABI-009 Cohort Dosing Schedule', 'Dose levels', 'ABI-009 in mg/m\u00b2', '-2', '1', '-1', '2.5', '1', '5', '2', '10', 'Version 2', 'Version Date: October 31, 2018', 'Page 35 of 72']['Protocol RS-001', 'Confidential', '3', '20', 'Escalation to the next dose level with a new cohort of 3 participants will occur after no DLT was', 'observed. There will be no intra-participant dose escalation allowed. If a DLT occurs in a cohort,', 'an additional 3 participants will be recruited to the cohort. If no further DLTs occur, then a new', 'cohort of 3 participants at the next higher dose level can be enrolled. If 2/6 participants at a dose', 'level experience a DLT, then the cohort will be closed to further enrollment and 3 participants', 'will be enrolled at the next lower dose level, and so on. The MTD is the highest dose level in', 'which 1 participant has a DLT. There will be no intra-participant dose escalation allowed.', 'Once the MTD has been determined, the MTD cohort will be opened for an estimated additional', '6 participants. These participants will adhere to the identical protocol of the rest of their cohort.', 'Product will be administered IV every 7 days for 3 weeks.', 'For a detailed review of visits, please see Appendix 1.', 'Total duration of the study is expected to be about one year.', '5', 'CRITERIA FOR EVALUATION', '5.1', 'Primary Enppoints', 'I. Safety', 'DLT and MTD', 'Incidence of adverse events and clinically significant abnormal lab values during dosing', 'II. Tolerability', 'Voluntary or medically-determined withdrawal from study', 'Adherence to medication regimen', 'C-SSRS serious suicidal ideation score stays below a 4 rating', '5.2', 'Secondary Enppoints', 'I.', 'Efficacy', 'Seizure frequency', 'Percentage reduction in seizure frequency', 'Median percentage reduction in seizure frequency', 'Response rate', 'Frequency of seizure-free days', 'Seizure-free rate', 'Rapamycin blood level-response relationship', 'II.', 'Quality of life and behavioral changes', 'Quality of Life for Children with Epilepsy Parent Form (QOLCE) [1] and', 'Version 2', 'Version Date: October 31, 2018', 'Page 36 of 72']\n\n###\n\n", "completion": "END"}